Physician profile
Robert Alejo Armada
NPI 1831274992
$872.57
in general payments reported to CMS, 2019-2025
18 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.42 · 2020: $50.93 · 2021: $36.02 · 2022: $56.72 · 2023: $334 · 2024: $148 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $657.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $112.36 | 2022-2025 | Wegovy |
| Daiichi Sankyo INC. | $109.27 | 2019-2023 | Injectafer |
| Abbvie INC. | $105.99 | 2021-2023 | Vraylar, Ubrelvy |
| Biogen, INC. | $81.51 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $74.76 | 2023-2024 | |
| Hologic Sales and Service, LLC | $66.73 | 2023-2024 | Novasure, Myosure Tissue Removal Device, Acessa Provu System |
| Exeltis, USA INC. | $53.59 | 2023-2025 | Slynd |
| Pfizer INC. | $36.91 | 2019-2023 | |
| Astellas Pharma US INC | $34.35 | 2024 | Veozah |
| Pacira Pharmaceuticals Incorporated | $33.04 | 2023 | Exparel |
| Sumitomo Pharma America, INC. | $32.01 | 2023-2025 | Gemtesa |
| Amag Pharmaceuticals, INC. | $26.95 | 2019-2020 | |
| Boston Scientific Corporation | $26.17 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.56 | 2022 | |
| Merck Sharp & Dohme LLC | $17.54 | 2023 | Gardasil 9 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.27 | 2025 | Interstim |
| Roche Diagnostics Corporation | $14.31 | 2020 | |
| Amgen INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Armada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.